Targeting the Triple-Negative Breast Cancer Kinome with Chemical Proteomics

Whittle, Martin C.

Targeting the Triple-Negative Breast Cancer Kinome with Chemical Proteomics Public Deposited

Analytics

Download PDF

Request Version for Screen Reader

Last Modified

March 20, 2019

Creator

Whittle, Martin C.
- Affiliation: School of Medicine, Department of Pharmacology

Abstract

Kinases are members of a large dynamic and cooperative signaling network, which senses inhibition of key nodal kinases and induces compensatory responses that offset pharmacological intervention. Combination therapies that target multiple growth- and survival promoting kinases are proving to be a better strategy for successful cancer therapy. What is lacking is the ability to measure whole kinome activity and to assess kinome adaptation and resistance to targeted therapies. We have developed a chemical proteomics approach that couples kinase affinity capture with quantitative mass spectrometry, providing a systems biology platform to profile global kinome activity in cancer cells, GEMM tumors and patient biopsies. Our chemical proteomic approach captures the majority of the expressed kinome estimated by RNA-seq and detects altered kinome activity profiles in response to stimulus or kinase inhibitors. Kinases from all major kinome subfamilies are captured with a large percentage representing the understudied kinome. Applying this technology, we discovered previously undefined activation of tyrosine and serine/threonine kinases in breast cancer cell lines in response to targeted inhibitors against MEK or EGFR that are currently undergoing clinical trials. Combined kinome activity assessment using chemical proteomics and RNAi synthetic lethal screens predicted a specific kinase inhibitor combination therapy. The combination therapy gave apoptosis and tumor regression in a breast cancer GEMM, where single agents were largely ineffective. The relevance of kinome reprogramming to patient triple-negative breast cancer was confirmed by the investigation of MEK inhibitor-treated patient samples from a window trial established in conjunction with GlaxoSmithKline. However, differential kinome responses were observed across intrinsic breast cancer subtypes, suggesting that broader approaches to targeting or preventing kinome reprogramming may be necessary to avert resistance to kinase inhibitor therapies. The findings presented here define a novel approach to determining kinome-based mechanisms of resistance to targeted therapies to suggest novel inhibitor combinations and strategies that may more effectively treat triple-negative breast cancer.

Date of publication